|Bid||60.9500 x 2200|
|Ask||60.9600 x 800|
|Day's Range||60.6300 - 61.3100|
|52 Week Range||52.8300 - 66.4100|
|PE Ratio (TTM)||105.73|
|Earnings Date||Jul 27, 2018|
|Forward Dividend & Yield||1.92 (3.10%)|
|1y Target Est||69.02|
At first blush, HPV vaccines and Chinese rice wine don’t have much in common. For a start, shares in both have been on a tear. Kweichow Moutai is up 65 percent over the past 12 months, while Zhifei Biological, Merck & Co.’s exclusive sales agent in China, has risen 135 percent. The China Food and Drug Administration has accelerated approvals for new vaccines: While Merck’s Gardasil, which protects against four strains of human papilloma virus, took 1,421 days to get the nod, Gardasil 9, which protects against nine types of HPV, got the regulatory stamp from Beijing in just eight days.
Merck & Company (MRK) reported revenue of $10.0 billion in the first quarter, a rise of ~6% year-over-year, and GAAP (generally accepted accounting principles) EPS of $0.27 compared to net revenue of $9.4 billion and GAAP EPS of $0.56 in the first quarter of 2017.
While cryptocurrencies like bitcoin are falling in value, the authors of the Blockchain Revolution insist its day has just begun. Don Tapscott and his son Alex, who co-authored the book, then founded the Blockchain Research Institute around it, are about to release an update, making this a good time to see where the revolution stands. A blockchain is simple in concept.
Big Pharma is struggling to keep up with the rest of the market this year as tepid revenue, growth, the expiration of key patents, and the likelihood of the government imposing tighter cost controls hold back its performance prospects. Earlier this month, while the broader S&P 500 was yielding just 2%, the dividend yield on the big drug companies in the index was nearly a full percentage point higher at 2.9%.
Dividend reinvestment is an amazingly powerful investment strategy. In fact, studies have shown that over a 20-year holding period, dividends account for 60% of all the gains in the S&P 500! Think about this for a minute. Since 1998, the S&P 500 would be around 60% lower if not for the benefits attributed to dividends.
Affimed NV (NASDAQ: AFMD ) shares were tumbling Friday after the release of updated data on its Hodgkin lymphoma treatment candidate. The metric investors are reacting to may be a decline in complete metabolic ...
Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.
Merck & Co Inc. (NYSE:MRK) is currently trading at a trailing P/E of 107.7x, which is higher than the industry average of 23.5x. Although some investors may jump to theRead More...
In spite of a strong start in 2018, the pharma/biotech industry is struggling currently, presumably due to a shift in focus to lowering of high drug prices and faster approval of generics. This has led to an increase in merger & acquisition activity and may boost innovation and capital building in the biotech industry. Earlier in the year, we have seen Sanofi SA (NYSE:SNY) and Celgene Corporation (NASDAQ:CELG) acquiring smaller biotech companies.
Merck's (MRK) Keytruda gets FDA approval for primary mediastinal B-cell lymphoma (PMBCL) - its second label expansion approval this week.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 13) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ...
Medical tourism has been a great business for Manna Wang, an insurance agent in Shenzhen who’s been helping Chinese women travel to Hong Kong for a vaccine against the human papillomavirus, or HPV, which can cause cervical cancer. In the two years since Merck & Co.’s Gardasil 9 became available in Hong Kong, about 2 million mainlanders have come for the shots, according to the Xinhua News Agency. With the drugmaker unable to keep up, some clinics are turning away Chinese patients, and angry mainlanders have protested at Merck’s local office.
Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA®, the company’s anti-PD-1 therapy, for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma , or who have relapsed after two or more prior lines of therapy.
Merck (MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) for GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant), the company’s 9-valent HPV vaccine. The application is seeking approval for an expanded age indication for GARDASIL 9 for use in women and men ages 27 to 45 for the prevention of certain cancers and diseases caused by the nine human papillomavirus (HPV) types covered by the vaccine. “Women and men ages 27 to 45 continue to be at risk for acquiring HPV, which can lead to cervical cancer and certain other HPV-related cancers and diseases,” said Dr. Alain Luxembourg, director, clinical research, Merck Research Laboratories.
Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA®, the company’s anti-PD-1 therapy, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 as determined by an FDA-approved test.
Eli Lilly (LLY) and AstraZeneca (AZN) are discontinuing two late-stage studies on their Alzheimer's disease candidate, lanabecestat.